Physician profile
Bryan Ross Walker
NPI 1497325690
$3,002.48
in general payments reported to CMS, 2019-2025
16 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.57 · 2023: $494 · 2024: $1,466 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,860 · Consulting Fee: $115 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,860.39 |
| Consulting Fee | $115.00 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $666.70 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $463.33 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $340.58 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $241.19 | 2024-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $225.02 | 2024-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $203.72 | 2023-2025 | Trintellix |
| Abbvie INC. | $174.89 | 2024-2025 | |
| Alkermes, INC. | $164.87 | 2023 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $151.03 | 2023-2025 | Ingrezza |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $88.86 | 2023-2024 | Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $78.22 | 2024 | |
| Biogen, INC. | $31.42 | 2025 | Zurzuvae |
| Bioxcel Therapeutics, INC. | $22.67 | 2023 | Igalmi |
| Lundbeck LLC | $18.10 | 2025 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $16.88 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.